Janssen submits NDA for YONDELIS to FDA to treat advanced soft tissue sarcoma
"We are particularly proud of this filing, as it represents our commitment to YONDELIS and the people it may help," said Peter F. Lebowitz, M.D., Ph.D., Global Oncology
ACROBiosystems has upgraded its global licence solution for HEK293 functional cell lines, aimed at streamlining compliance to expedite biopharmaceutical research and development (R&D).
FTC has also approved creation of a consumer healthcare joint venture (JV) by combining GSK’s Consumer Healthcare business and Novartis’ over-the-counter (OTC) Consumer Healthcare business. Novartis has agreed